I am delighted that this particular paper has been so certain, we tested the effects of the D-enantiomer -it was highly cited as I always assumed that it had been rather devoid of activity -and showed that the effects of Lovershadowed by its sibling paper that we published in NMMA could be reversed by L-arginine but not by DThe Lancet [1] . In 1987 I started work with Joe Collier arginine. At the time this was exciting because it was the trying to determine whether endothelium-dependent relaxafirst demonstration of the existence of the L-arginine:nitric tion occurred in human vessels in vivo. We worked in the oxide pathway in humans. Later it became interesting to us veins since we wanted to damage the endothelium exin a different way when we realised that the arterial perimentally and to do so in arteries would have been circulation constricted to L-NMMA, and it thus became risky. By infusing distilled water into the lumen of a vein clear that basal nitric oxide-mediated dilatation was a on the back of the hand we managed to denude the vessel feature of the arterial circulation but was not evident in of its endothelium and this procedure was associated with veins. This observation turned out to be relevant to loss of responsiveness to acetylcholine. Soon after this understanding why nitric oxide donor drugs show venexperiment, Salvador Moncada's group published in Naoselectivity. Similar observations had not been made in the ture [2] that Furchgott's endothelium-derived relaxing animal or in vitro studies and the finding was a further factor (EDRF) was nitric oxide synthesised from L-arjustification for continuing to work in humans and in veins. ginine and that the synthetic process could be inhibited by Looking back, two things come to mind (i) this work was G the arginine analogue, N monomethyl-L-arginine (Ldifficult to get funded and I remain grateful to the South NMMA). It seemed obvious that we should explore the West Thames Regional Health Authority for having the effects of L-NMMA in the hand vein model. I had never courage to fund it, and (ii) it was even more difficult to get met Salvador Moncada before but he did not need much it published. Indeed it is because of the delays and eventual persuasion. We had little in the way of formal toxicology rejection we encountered at the hands of another (namefor L-NMMA but there was a significant amount of animal less) journal, that our subsequent work on the effects of pharmacology available and we planned to give doses of L-NMMA in the arterial circulation was published in The L-NMMA that would produce an effective concentration in Lancet before this paper appeared in Cardiovascular a single hand vein, but which would be far below a
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Research. Ten years on I am very pleased that it has been systemically-effective concentration. such a highly cited paper and I wouldn't mind recapturing The initial studies were a disappointment; L-NMMA did that sense of excitement with another project. nothing on its own and did not enhance the constrictor response to noradrenaline. However, when we got on to the dilator studies everything fell into place. L-NMMA References abolished the dilatation to acetylcholine, blunted the dilatation to bradykinin but did not affect the response to
